ACB

Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.

Aurora criticized key aspects of the bid, but will consider it. The major appeal of Aurora is its strong medical marijuana business.

EDMONTON, AB, Aug. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, responded today to a press release issued by Curaleaf Holdings, Inc. ("Curaleaf") regarding its stated intention to launch an unsolicited take-over bid for all of the issued and outstanding common shares of the Company (the "Aurora Shares") at a stated implied consideration of US$4.00 per Share, consisting of 0.3463 subordinate voting shares of Curaleaf plus US$0.75 in cash per Aurora Share (the "Proposal"). Aurora confirms that it received letters from Curaleaf dated June 23, 2026 and July 7, 2026 outlining proposals to acquire the Aurora Shares.

Curaleaf Hldgs Inc. (OTCQX:CURLF) has launched a hostile bid to acquire Aurora Cannabis Inc (TSX:ACB, NASDAQ:ACB), offering Aurora shareholders a combination of Curaleaf shares and cash that values the proposal at US$4 per Aurora share, as it seeks to combine the companies' international cannabis operations. Under the proposed transaction, Aurora shareholders would receive 0.3463 Curaleaf shares plus US$0.75 in cash for each Aurora share.

Proposed Offer reflects a 45% premium to Aurora's 30-day VWAP and a 110% premium to Aurora's 30-day VWAP excluding balance sheet cash  Provides Aurora shareholders with the opportunity to become owners of the premier global cannabis platform and participate in the significant long-term upside of the combined company Combines Aurora's EU-GMP cultivation and manufacturing capacity with Curaleaf's EU-GMP processing capabilities and international distribution platform to immediately enhance combined margins and accelerate patient access across Europe, Canada, Australia, and New Zealand Urges Aurora's Board to engage in good-faith discussions regarding the proposed transaction STAMFORD, Conn., Aug. 11, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announces its intention to make an offer (the "Offer") to purchase all of the issued and outstanding common shares (the "Aurora Shares") of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora") for consideration consisting of subordinate voting shares of Curaleaf (the "Curaleaf Shares") and cash.

EDMONTON, AB, Aug. 10, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora" or the "Company"), the Canadian-based leading global medical cannabis company, is pleased to announce the voting results from its Annual General Meeting of Shareholders (the "Meeting") held Friday August 7, 2026 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 16,639,306 common shares, representing 26.86% of Aurora's issued and outstanding common shares as of the record date.

Aurora Cannabis NASDAQ: ACB said shareholders approved all items presented at its annual general meeting, including setting the board size at five directors, electing the company's nominees, reappointing Ernst & Young LLP as auditor, and approving its non-binding advisory vote on executive compensation.

Aurora Cannabis Inc. (ACB:CA) Q1 2027 Earnings Call Transcript

Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to a loss of $0.19 per share a year ago.

Aurora Cannabis NASDAQ: ACB reported fiscal first-quarter 2027 net revenue of C$67.6 million, as growth in international medical cannabis sales was offset by lower Canadian medical revenue following reimbursement changes and the company's planned exit from lower-margin Canadian consumer cannabis operations.